Molecular risk factors of skull base chordomas
| Project/Area Number |
24791519
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 頭蓋底 / 脊索腫 / brachyury / T遺伝子 / 2番染色体 / chordoma / CGH / FISH |
|---|
| Research Abstract |
Chordoma is an invasive tumor that develops from notochordal remnants and frequently occurs in skull base. T gene and its product (brachyury) have been recently suggested to play an important role in chordoma progression. We analyzed skull base chordomas for chromosomal copy number aberrations by comparative genomic hybridization, brachyury expression by immunohistochemistry, and T gene copy number by fluorescence in situ hybridization. Statistical analyses demonstrated that losses on chromosome 1p and gains on 1q, 2p, expression of brachyury, and gain of T gene were significantly associated with shorter progression free survival. Our results suggest that brachyury-negative chordomas are biologically distinct from brachyury-positive chordomas, and T/brachyury might be one of the best molecular therapeutic targets of chordoma.
|
Report
(3 results)
Research Products
(10 results)
